These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2225313)

  • 1. Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
    Kreis W; Budman DR; Freeman J; Bergstrom RF; Nelson RL
    Cancer Chemother Pharmacol; 1990; 26(6):419-22. PubMed ID: 2225313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of vinzolidine.
    Kreis W; Budman DR; Schulman P; Freeman J; Greist A; Nelson RL; Marks M; Kevill L
    Cancer Chemother Pharmacol; 1986; 16(1):70-4. PubMed ID: 3940223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of intravenous vinzolidine.
    Taylor CW; Salmon SE; Satterlee WG; Robertone AB; McCloskey TM; Holdsworth MT; Plezia PM; Alberts DS
    Invest New Drugs; 1990; 8 Suppl 1():S51-7. PubMed ID: 2380017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.
    Budman DR; Kreis W; Behr J; Schulman P; Lichtman S; Allen SL; Weiselberg L; Satterlee WG; Nelson RL; Vinciguerra V
    Invest New Drugs; 1990 Aug; 8(3):269-74. PubMed ID: 2272767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
    Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
    Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.
    Takasugi BJ; Robertone AB; Salmon SE; Jones SE; Alberts DS
    Invest New Drugs; 1984; 2(4):387-90. PubMed ID: 6096287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative.
    Ings RM; Lelièvre E; Ardiet C; Clavel M; Leyvraz S; Minaidis D; Lokiec F; Turpin F; Solere P; Lucas C
    Xenobiotica; 1992 Jul; 22(7):871-80. PubMed ID: 1455905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vinpocetine in humans.
    Vereczkey L; Czira G; Tamás J; Szentirmay Z; Botár Z; Szporny L
    Arzneimittelforschung; 1979; 29(6):957-60. PubMed ID: 582791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats.
    Jiang C; Li J; Cai X; Li N; Guo Y; Wang D
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30646543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
    Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
    van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
    Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics.
    Szeleczky G; Vereczkey L
    Pol J Pharmacol Pharm; 1986; 38(3):257-67. PubMed ID: 3774624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
    van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
    J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.